[Tumor chemotherapy of ovarian cancer patients in advanced age].
Retrospectively the side effects caused by toxicity of cis-platinum chemotherapy combinations, the prolongation of the intervals in tumour chemotherapy without treatment determined by this, and the interruption of therapy caused by this 23 patients with ovarian cancer at an age of below 55 (average age 49.6 years) were contrasted with those of 25 patients with ovarian cancer, aged above 55. By means of the convergence table no significant differences in toxicity between the two age groups could be discerned at an error probability of 10 per cent. According to our experience the advanced age does not present any essential contra-indication for tumour chemotherapy in patients with ovarian cancer.
Behling
H
H
Klinik und Poliklinik für Gynäkologie und Geburtshilfe, Medizinischen Akademie Erfurt.
Schirmer
A
A
Krafft
W
W
Brückmann
D
D
D000367:Age Factors; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*
D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin
Die Tumorchemotherapie bei Ovarialkarzinompatientinnen im fortgeschrittenen Lebensalter.